论文部分内容阅读
目的:观察国产与进口单唾液酸四己糖神经节苷脂(GM1)治疗小儿脑性瘫痪的临床疗效。方法:83例脑瘫惠儿分为国产组(42例)和进口组(41例),两组患儿均采用常规训练和治疗,同时分别给予国产和进口单唾液酸四己糖神经节苷脂,比较两组疗效和安全性,结果:治疗后,国产组和进口组的总有效率、粗大运动功能评分(GMFM)和精细运动功能评分(FMFM)及不良反应发生率差异均无统计学意义(P>0.05)。结论:凶产与进口单唾液酸四己糖神经节苷脂治疗小儿脑性瘫痪有相似的临床疗效。
Objective: To observe the clinical efficacy of domestic and imported monosialotetrahexosyl gangliosides (GM1) in the treatment of children with cerebral palsy. Methods: Eighty-three cases of children with cerebral palsy were divided into two groups: domestic group (42 cases) and import group (41 cases). Both groups were given routine training and treatment. At the same time, both domestic and imported monosialotetrahexosyl gangliosides , The curative effect and safety of the two groups were compared. Results: After treatment, there was no significant difference in total effective rate, gross motor function score (GMFM), fine motor function score (FMFM) and incidence of adverse reactions between the domestic group and the imported group (P> 0.05). Conclusion: Fetal and imported monosialotetrahexosyl gangliosides in children with cerebral palsy have similar clinical efficacy.